Nephritis, phospholipid antibodies contribute to cardiovascular risk in lupus

DESTIN, Fla. — Nephritis and phospholipid antibodies should be considered as contributors to cardiovascular disease risk in patients with systemic lupus erythematosus, according to a speaker at the Congress of Clinical Rheumatology East.
“In my view, I think that cardiovascular disease in SLE is an enemy with two major faces,” Elisabet Svenungsson, MD, PhD, an adjunct professor from the Karolinska Institute, in Sweden, told attendees. “It’s the nephritis patients who are about 30% to 40%, at least at our center. The other face is the phospholipid antibodies.”

DESTIN, Fla. — Nephritis and phospholipid antibodies should be considered as contributors to cardiovascular disease risk in patients with systemic lupus erythematosus, according to a speaker at the Congress of Clinical Rheumatology East.
“In my view, I think that cardiovascular disease in SLE is an enemy with two major faces,” Elisabet Svenungsson, MD, PhD, an adjunct professor from the Karolinska Institute, in Sweden, told attendees. “It’s the nephritis patients who are about 30% to 40%, at least at our center. The other face is the phospholipid antibodies.”